Looks like this event has already ended.
Explore the events happening around you, or organize your very own event.
Biotech companies used to think about how to build enduring companies with soup-to-nuts operations that had everything under one corporate flag, from research to development to manufacturing to marketing. Those models increasingly look like relics. Investors have grown weary of the long timelines, big bucks, and high risk that comes with building such organizations. Stung by losses, a number of VCs, entrepreneurs and investors are turning to small core teams that lean heavily on contract firms to try to make biotech more nimble, less capital intensive, and a more attractive industry for investment. Come join Xconomy for a number of case studies and interactive chats with national leaders who are looking to reinvent the biotech business model.
Corey Goodman, Partner, venBio
John Maraganore, CEO, Alnylam Pharmaceuticals
Kevin Starr, Partner, Third Rock Ventures
Kathy Glaub, President, Plexxikon
Carl Weissman, CEO, Accelerator
Thong Le, Managing Director, WRF Capital
Bruce Montgomery, CEO, Cardeas Pharma
Heather Franklin, CEO, Blaze Bioscience
Peppi Prasit, Founder, Inception Sciences
David McElligott, Chief Scientific Officer, Groove Biopharma
Steve Tregay, CEO, Forma Therapeutics
Brian Atwood, Managing Director, Versant Ventures
Alex Lash, Biopharma editor, Start-Up, In Vivo
Ed Saltzman, President, Defined Health
Cliff Stocks, CEO, Theraclone Sciences
John Mendlein, CEO, aTyr Pharma
Registration: 1:00 – 2:00 pm
Program: 2:00 – 6:00 pm
Networking Reception: 6:00 – 7:00 pm
Tickets are transferable but not refundable.
To inquire about press registration, e-mail email@example.com.
Alexandria Real Estate • BDO • Christensen O'Connor Johnson Kindness
Cooley LLP • Davis Wright Tremaine • Fenwick & West LLP
Graham & Dunn • IDA Ireland • Institute for Systems Biology
Kauffman Foundation • Kilpatrick Townsend • Puget Sound Blood Center
VENTURE CAPITAL MEMBERS
ARCH Venture Partners • Vulcan Capital • WRF Capital